American bank says Centrica's transformation deserves a higher valuation

JP Morgan has reiterated an 'overweight' on Centrica with a street-high 224p price target (c.19% upside) arguing a 14% EPS CAGR and a shift from zero to ~25% of group EBITDA from regulated/contracted infrastructure by 2030 justifies a re-rating. The bank flags a transformation cost up to £600m and acknowledges execution risk, models below consensus for 2026–27 but is ~7% above for 2028–29 and ~15% above for 2030, and expects Centrica to remain net cash in 2030 with >£2bn headroom for M&A or buybacks; near-term catalysts include gas-storage remuneration clarity, nuclear life extensions and AMR progress. Shares were trading at 191.71p, up 1.8% in late morning trade.

Analysis

Market structure: Centrica's pivot toward ~25% regulated/contracted EBITDA by 2030 shifts it from a volatile retail/trading profile to utility-like cashflow, directly benefiting Centrica (LSE:CNA), nuclear services contractors, and gas-storage asset owners while hurting pure-play retail traders and short-duration wholesale generators whose relative valuation should compress. Pricing power will move toward contracted returns (lower beta, higher multiple); expect Centrica's equity volatility to fall and credit spreads to tighten if JPM's cash-positive 2030 scenario holds (net cash >£2bn headroom). Cross-asset: sterling could firm modestly on a clearer UK energy earnings stream, corporate bonds (CNA) may tighten by 50–150bp over 12–24 months, and short-term gas trading revenues remain a commodity sensitivity.

Risk assessment: Key tail risks are regulatory reversals on gas-storage remuneration (policy risk), failed nuclear life extensions or major capex overruns on AMR (operational), and a UK political push to curb buybacks (sovereign/regulatory). Immediate (days-weeks) sensitivity centers on JP Morgan headlines and Ofgem comments; short-term (3–12 months) depends on remuneration framework and nuclear decisions; long-term (to 2030) hinges on execution of the £600m programme and realized shift to contracted EBITDA. Hidden dependencies include wholesale price assumptions for trading earnings and government support for AMR—both amplify upside or sink valuation if outcomes diverge.

Key Decisions for Investors

• Establish a 2–3% long position in Centrica (LSE:CNA) within 30 days, target 224p in 6–12 months, set a tactical stop-loss at 165p (≈-14%) and trim to half position if price reaches 224p or if Ofgem guidance on gas storage is negative.
• Buy a Dec-2026 CNA 200/260 call spread sized 0.5–1% notional as a leveraged upside play; roll or realize if CNA >260p or if nuclear life-extension announcements are confirmed (expected 6–12 months).
• Implement a pair trade: long CNA (2%) vs short SSE (LSE:SSE) (1.5% size to be delta-neutral) to capture re-rating differential; target 20–30% relative outperformance over 12–24 months, exit or rebalance on evidence of regulatory headwinds.
• Monitor three specific catalysts in the next 90 days and act: (1) Ofgem gas-storage remuneration framework – if it permits IRR >7% for storage, add 1% to CNA; (2) confirmation of existing nuclear life-extensions – if positive, increase call-spread size; (3) any government/Ofgem curbs on buybacks – if announced, reduce CNA exposure to ≤1%.